Back to the main directory
EarningsReview / Equity
- Q423 results and 15 questions for management by BNP Paribas Exane
- New strategy de-risks balance sheet and front-loads profits by BNP Paribas Exane
- Sparebank 1 SMN (Buy, TP: NOK161.00) - Continued core revenue momentum by DnB Markets
- SpareBank 1 Helgeland (Hold, TP: NOK145.00) - Q4 ROE hit by elevated loan losses by DnB Markets
- ALK-Abello (Buy, TP: DKK140.00) - Q3 rebound was not a one-off by DnB Markets
- XXL (Hold, TP: NOK0.80) - Running out of runway by DnB Markets
- Aker Solutions (Hold, TP: NOK40.00) - Larger SOTP discount warranted by DnB Markets
- Höegh Autoliners ASA (Buy, TP: NOK160.00) - One bird in hand, more on the roof by DnB Markets
- Sparebanken Sør (Buy, TP: NOK159.00) - Further NII and cost expansion by DnB Markets
- Metsa Board (Hold, TP: EUR7.70) - Evidence of improving markets by DnB Markets
- Catella (Buy, TP: SEK34.00) - Awaiting real estate recovery by DnB Markets
- Balder (Hold, TP: SEK67.00) - A market interest rate case by DnB Markets
- Kongsberg Gruppen (Buy, TP: NOK680.00) - Solid earnings trajectory by DnB Markets
- Seafood - Fat Trout Weekly by DnB Markets
- Weekly news, topics & discussion by DnB Markets
- Widening gap in asset writedowns by DnB Markets
- Balder - Out of the woods by Danske Bank Equity Research
- Entra (Hold, TP: NOK115.00) - Q4 in line, potential for divestments by DnB Markets
- Ambea (Buy, TP: SEK76.00) - Yet another strong showing by DnB Markets
- Humana (Hold, TP: SEK27.00) - Never a good time to leave by DnB Markets
- The weekly navigator by DnB Markets
- January global trends: Demand signals mixed by BNP Paribas Exane
- Carlsberg A/S (CARLB DC) by HSBC
- Sitting In The Catbird Seat Of AI Networking Components by BNP Paribas Exane
- Kemira - Weakening earnings momentum limits upside by Danske Bank Equity Research
- Second half surprises by BNP Paribas Exane
- Another solid year by BNP Paribas Exane
- SpareBank1 SR-Bank (Buy, TP: NOK163.00) - Strong Q4, but CET1 ratio downtick by DnB Markets
- SpareBank 1 Sørøst-Norge (Hold, TP: NOK66.00) - SpareBank 1 Sør-Norge on the horizon by DnB Markets
- Otovo (Hold, TP: NOK2.60) - Needs to rebuild investor trust by DnB Markets
- SpareBank 1 Østlandet (Buy, TP: NOK140.00) - Sustained NII uptick, but cost pressure by DnB Markets
- GN Group (Buy, TP: DKK215.00) - Solid 2024 market outlook by DnB Markets
- A. P. Møller Mærsk (Sell, TP: DKK9500.00) - No relief in sight by DnB Markets
- Sparebanken Øst (Hold, TP: NOK51.00) - Generous dividend capacity by DnB Markets
- Yara (Buy, TP: NOK425.00) - Ending a bad year on a good note by DnB Markets
- Coloplast (Buy, TP: DKK1000.00) - Strong start to the year by DnB Markets
- Kemira (Buy, TP: EUR21.00) - Quality at a discount by DnB Markets
- Bergman & Beving (Buy, TP: SEK200.00) - New target ‘500/10/45’ by 2025/27 by DnB Markets
- Sweco Minor model adjustments by DnB Markets
- Valuation and market update by DnB Markets
- Bergman & Beving - Showing robustness and agility by Danske Bank Equity Research
- Scandi Standard - Coming down for a layover by Danske Bank Equity Research
- Skanska (Buy, TP: SEK225.00) - Q4 raises our SOTP by DnB Markets
- Gentian Diagnostics (Buy, TP: NOK54.00) - A (EBITDA-)positive year by DnB Markets
- Sweco (Buy, TP: SEK137.00) - Q4 profitability headwind set to ease by DnB Markets
- Margin continues to disappoint by BNP Paribas Exane
- EV ramp-up hurting margin by BNP Paribas Exane
- Don’t Lose The Forest For The Trees by BNP Paribas Exane
- A Key Enabler Of An Expanding AI TAM by BNP Paribas Exane
- Coloplast - Margin progress, but recovery may still prove bumpy by Danske Bank Equity Research